US District Court rules in favor of Neuralstem in patent infringement case

24 July 2015

USA-based stem cell development firm Neuralstem (NYSE Amex: CUR) said yesterday that the US District Court for the District of Maryland dismissed StemCells’ patent infringement case with prejudice in StemCells Inc v Neuralstem Inc in favor of Neuralstem, on July 22, 2015.

Shares of Neuralstem leapt 14.9% to $1.93 by close of trading on Thursday, after the news was announced.

The District Court held a bench trial on the issue of standing in December of 2014. In its 29-page Memorandum Opinion, the US District Court for the District of Maryland ruled that a third-party scientist is a co-owner and co-inventor of the patents-in-suit. As a result, StemCells lacked standing on its own to bring its patent infringement claims against Neuralstem and the case was dismissed with prejudice.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK